TRUTAKNA Cuts Kidney Disease Progression by 76% in Phase 3, Setting Stage for Full Approval
VERA sits 66% above its 52-week low of $22.72.
Summary
Vera Therapeutics announced final efficacy results from the ORIGIN 3 trial showing TRUTAKNA stabilized eGFR and reduced kidney disease progression events by 76% (HR 0.24) compared to placebo in IgA nephropathy patients. The drug also showed zero dialysis, transplant, or death events versus 8 in the placebo arm. These results support a supplemental BLA submission planned for Q4 2026, with potential full approval in 2027. The company also reported strong early commercial traction with over 350 patient start forms in the first 10 weeks since accelerated approval. This data significantly de-risks the confirmatory trial requirement and strengthens the case for full approval, which would expand the label and market opportunity.
At the time of this announcement, VERA was trading at $37.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $22.72 to $56.05. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.